Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

TPB Publications

2000 Abstracts/Presentations

  1. Mirsalis, J, Schindler-Horvat, J, Fairchild, D, Schweikart, K, Donohue, S, Tomaszewski, J and Tyson, C, 2000. Species Differences in Target Organ Effects of Benzoylphenylurea (BPU) in Rats and Dogs. [Abstract No. 1919]. The Toxicologist, 54 (1-S): 409.
  2. Brown, A.P., Morrissey, R.L., Smith, A.C., Tomaszewski, J.E., and Levine, B.S. 2000. Comparison of 8-Chloroadenosine (NSC-354258) and 8-Chloro-cyclic-AMP (NSC-614491) Toxicity in Dogs. [Abstract No. 3132]. Proc. Amer. Assoc. Cancer Res., 41, 491.
  3. Chang, C.J.G., Smith, A.C., Fulton, R., Farnell, D.R., Lin, T.H., Emory, M.B., Page, J.G. 2000. 120-Hour Infusion Dose Range-Finding Study of 2'-Fluoro-ara-Deoxyuridine (FAU, NSC-678515) in Beagle Dogs. [Abstract No. 4472]. Proc. Amer. Assoc. Cancer Res., 41, 703.
  4. Chan, K.K., Chiu, M., and Covey, J. 2000. GC/MS and Stable Isotope Dilution Assay for the Radiation Protecting Agent Tempol (NSC-142784) and Reduced Tempol in Plasma. [Abstract No. 4485]. Proc. Amer. Assoc. Cancer Res., 41, 705.
  5. Chen, W., Gandhi, V., Rhie, J. K., Ayres, M., Felix, E. and Newman, R.A. 2000. Plasma and Cellular Pharmacology of 8-Chloro-Adenosine (NSC-354258) in Mice. [Abstract No. 4451]. Proc. Amer. Assoc. Cancer Res., 41, 700.
  6. Covey, J.M., Chan, K.K., and Chiu, M. 2000. Pharmacokinetics of Tempol (NSC-142784) and Reduced Tempol in the Rat as Measured by a Specific GC/MS assay. [Abstract No. 4484]. Proc. Amer. Assoc. Cancer Res., 41, 705.
  7. Eiseman, J.L., Sentz, D.L., Rosen, D.M., Zuthowski, E.G., White, K.D., Musser, S.M., Egorin, M.J. 2000. Murine Plasma Pharmacokinetics of the Hybrid Polar Compound, Pyroxamide (NSC-696085). [Abstract No. 4903]. Proc. Amer. Assoc. Cancer Res., 41, 771.
  8. Hale, J., Bigelow, J., Mathews, L., McCormack, J., Torti, S., Torti, F., Brechbiel, M., and Planalp, R. 2000. Analytical and Pharmacokinetic Studies in Mice with Tachpyr. [Abstract No. 4483]. Proc. Amer. Assoc. Cancer Res., 41, 705.
  9. Kuffel, M.J., Bowman, S.L., Browne, J.A., Reid, J.M., Naylor, S., and Ames, M.M. 2000. Tumor Cell and Tissue-Selective Cytochromes P450 Oxidation of Aminoflavone Analog NSC-686288. [Abstract No. 2347]. Proc. Amer. Assoc. Cancer Res., 41, 370.
  10. Lin, T.H., Noker, P.E., Johnson, J.D., Rhie, J.K. 2000. Pharmacokinetics of a Novel Antifolate, PT523, in Mice and Rats. [Abstract No. 3129]. Proc. Amer. Assoc. Cancer Res., 41, 490.
  11. Lin, T.H., Chang, C.J.G., Noker, P.E., Smith, A.C., Page, J.G. 2000. Disposition of 2'-Fluoro-ara-Deoxyuridine (FAU, NSC-678515) in Beagle Dogs. [Abstract No. 4471]. Proc. Amer. Assoc. Cancer Res., 41, 703.
  12. McCormick, D.L., Johnson, W.D., Pribluda, V.S., Green, S.J., Tomaszewski, J.E., Smith, A.C. 2000. Preclinical Development of 2-Methoxyestradiol (2ME2, NSC-659853). [Abstract No. 2080]. Proc. Amer. Assoc. Cancer Res., 41, 328.
  13. Noker, P.E., Lin, T.H., Smith, A.C., Page, J.G. 2000. Pharmacokinetics of Pyroxamide (NSC-696085), A Hybrid Polar Compound, in Beagle Dogs. [Abstract No. 4904]. Proc. Amer. Assoc. Cancer Res., 41, 772.
  14. Noker, P.E., Chang, C.J.C., Smith, A.C., and Page, J.G., 2000. Preclinical Toxicology of Pyroxamide (NSC-696085) in Dogs and Rats. [Abstract No. 4902]. Proc. Amer. Assoc. Cancer Res., 41, 771.
  15. Squillace, D.P., Ruben, S.L., Reid, J.M. and Ames, M.M., 2000. HPLC Analysis and Murine Pharmacokinetics of the Cytotoxic Bioreductive Agent NLCQ-1 (NSC-709257). [Abstract No. 4488]. Proc. Amer. Assoc. Cancer Res., 41, 706.
  16. Tomaszewski, J.E., Schweikart, K.M., Turner, N.A., Tosca, P.J., Hassler, C.R., Prezioso, J.A., Ryan, M.J., Giedlin, M., Bouchard, P., Wiltrout, R., and Wigginton, J., 2000. Toxicological Evaluation of Interleukin-12/Interleukin-2 (IL-12/IL-2) Combination in Cynomolgus Monkeys. [Abstract No. 4475]. Proc. Amer. Assoc. Cancer Res., 41, 704.
  17. Tosca, P.J., Turner, N., Ryan, M., Yarrington, J., Bollinger, L., Long, H., Schweikart, K. and Tomaszewski, J.E. ,2000. Toxicity of R(+) XK469 (NSC-698215) and S(-) XK469 (NSC-698216) in Rodents and Beagle Dogs. [Abstract No. 4480]. Proc. Amer. Assoc. Cancer Res., 41, 705.
  18. Pribluda, V.S., LaVallee, T.M., Swartz, G.M., Fogler, W.E., Smith, A.C., Tomaszewski, J.E., Gubish, E.R., and Green, S.J., 2000. From Bench to Bedside: The Pharmaceutical Development of 2-Methoxyestradiol, A Potent Orally Active Antiangiogenic and Antitumor Agent. 25th ESMO Congress at Hamburg, Germany.
  19. Zheng, HH, Chan, KK, and Covey JM, 2000. Enantioselective determination of (R+)- and S(-)XK469, an antitumor agent, in rat plasma by chiral HPLC. AAPS PharmSci. 2 (Supp.), AAPS Annual Meeting Abstracts.

About the Branch Chief

For information regarding the TPB, please contact Dr. Jerry M. Collins, Associate Director, collinsje@mail.nih.gov